^
BIOMARKER:
TP53 mutation
i
Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
Entrez ID:
TP53 mutation
CLL
venetoclax + obinutuzumab
Sensitive
:
A1
TP53 mutation
CLL
venetoclax
Sensitive
:
A1
TP53 mutation
CLL
rituximab + idelalisib
Sensitive
:
A1
TP53 mutation
CLL
acalabrutinib
Sensitive
:
A1
TP53 mutation
CLL
idelalisib + ofatumumab
Sensitive
:
A1
TP53 mutation
CLL
rituximab + alemtuzumab
Sensitive
:
A2
TP53 mutation
CLL
venetoclax + rituximab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive
:
A2
TP53 mutation
CLL
zanubrutinib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
rituximab
Sensitive
:
A2
TP53 mutation
CLL
ibrutinib
Sensitive
:
A2
TP53 mutation
CLL
ofatumumab
Resistant
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
ibrutinib
Sensitive
:
A2
TP53 mutation
CLL
idelalisib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
ofatumumab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
idelalisib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
rituximab + idelalisib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
duvelisib
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax + rituximab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
obinutuzumab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
alemtuzumab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
rituximab + alemtuzumab
Sensitive
:
A2
TP53 mutation
Small Lymphocytic Lymphoma
venetoclax + obinutuzumab
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our